Foghorn Therapeutics will present at three upcoming healthcare conferences, focusing on its innovative gene expression therapies.
Quiver AI Summary
Foghorn Therapeutics Inc. announced its participation in several healthcare conferences, including the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. President and CEO Adrian Gottschalk will present at these events, focusing on Foghorn's Gene Traffic Control platform, which targets abnormal gene expression to develop innovative treatments, particularly in oncology. The company aims to address various diseases by discovering and validating drug targets within the chromatin regulatory system. Webcasts of the presentations will be available on the company’s website.
Potential Positives
- Foghorn Therapeutics is engaging with key stakeholders by participating in multiple prominent healthcare conferences, enhancing its visibility in the biotech industry.
- The presentation of Foghorn's innovative Gene Traffic Control® platform at these conferences demonstrates the company's commitment to transforming treatment options in oncology.
- Having the CEO, Adrian Gottschalk, represent the company at high-profile events highlights the credibility and leadership behind Foghorn's strategic direction.
Potential Negatives
- There is no indication of recent clinical trial results or advancements in their drug development pipeline, which may raise concerns about the progress and viability of their therapies.
- The company is participating in multiple healthcare conferences, which may suggest that they are seeking additional funding or partnerships, indicating potential financial instability.
- Overall, the press release does not provide any new information regarding product advancements or financial performance, which could be viewed as a lack of transparency or progress.
FAQ
What conferences will Foghorn Therapeutics participate in?
Foghorn Therapeutics will participate in the Guggenheim, Stifel, and Jefferies Healthcare Conferences.
Who is presenting for Foghorn Therapeutics?
Adrian Gottschalk, President and CEO, will present at all three conferences.
When is the Guggenheim Healthcare Innovation Conference?
The Guggenheim Conference is on November 10, 2025, at 11:00 a.m. ET.
How can I access the presentation webcasts?
The presentation webcasts can be accessed in the “Events & Presentations” section on Foghorn's website.
What is Foghorn’s focus in biotechnology?
Foghorn focuses on developing medicines for oncology by correcting abnormal gene expression.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FHTX Hedge Fund Activity
We have seen 44 institutional investors add shares of $FHTX stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,477,989 shares (+318.7%) to their portfolio in Q2 2025, for an estimated $11,646,548
- BLACKROCK, INC. added 233,232 shares (+11.7%) to their portfolio in Q2 2025, for an estimated $1,096,190
- CANTOR FITZGERALD, L. P. added 150,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $705,000
- RAYMOND JAMES FINANCIAL INC added 148,940 shares (+6.7%) to their portfolio in Q2 2025, for an estimated $700,018
- GEODE CAPITAL MANAGEMENT, LLC added 116,979 shares (+16.9%) to their portfolio in Q2 2025, for an estimated $549,801
- AMERIPRISE FINANCIAL INC added 112,237 shares (+inf%) to their portfolio in Q2 2025, for an estimated $527,513
- ROCKWOOD WEALTH MANAGEMENT, LLC removed 107,329 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $504,446
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FHTX Analyst Ratings
Wall Street analysts have issued reports on $FHTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 05/15/2025
To track analyst ratings and price targets for $FHTX, check out Quiver Quantitative's $FHTX forecast page.
Full Release
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Guggenheim Second Annual Healthcare Innovation Conference
- Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
-
Management will also participate in one-on-one meetings
Stifel 2025 Healthcare Conference
- Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
-
Management will also participate in one-on-one meetings
Jefferies 2025 London Healthcare Conference
- Fireside Chat: Wednesday, November 19, 2025, at 10:30 a.m. GMT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
-
Management will also participate in one-on-one meetings
A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.
About Foghorn Therapeutics
Foghorn
®
Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control
®
platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at
www.foghorntx.com
for more information on the Company, and follow us on
X
and
LinkedIn
.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
[email protected]
